Navigation Links
DSM and Codexis Sign Enzyme Supply Agreement
Date:1/12/2011

PARSIPPANY, N.J. and REDWOOD CITY, Calif., Jan. 12, 2011 /PRNewswire/ -- The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn™ route scouting services.

Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste.  Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.

The DSM InnoSyn™ route scouting team provides value creating solutions to its customer by integrating cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.

"Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners," said Joseph Sarret, M.D., President, Codexis Pharmaceutical Services & Enzyme Products. "We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale."

Oliver May, Ph.D., Corporate Scientist and Business Manager for DSM's InnoSyn™ route scouting services commented: "One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM's capabilities to identify, develop and implement efficient enzymatic routes."

InnoSyn™ is a trademark of DSM

Codexis Codexis (Nasdaq: CDXS) is a clean technology company that develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with many leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals. More information: www.codexis.com

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information:  www.dsmpharmaceuticalproducts.com

DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about Euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

Codexis Forward-Looking StatementsThis press release contains forward-looking statements relating to Codexis development of biocatalysts for use at DSM Pharmaceutical Products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis Quarterly Report on Form 10-Q dated November 4, 2010 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

DSM Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.For more information:DSMCodexisOliver May, Ph.D.

Media: Lyn ChristensonBusiness Manager, InnoSyn™

tel. +1 650 421 8144 tel. +31 (46) 4760551

lyn.christenson@codexis.com oroliver.may@dsm.com

Saskia Sidenfadentel. +1 212 827 3771ssidenfaden@mww.com   Investors: Robert Lawson tel. 650 421 8137robert.lawson@codexis.com
'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Atomic-resolution views suggest function of enzyme that regulates light-detecting signals in eye
2. New insight into the controls on a go-to enzyme
3. UNC scientists teach enzyme to make synthetic heparin in more varieties
4. Rare disease provides clues about enzyme role in arrhythmias
5. Brain enzyme may play key role in controlling appetite and weight gain
6. Newly found enzymes may play early role in cancer
7. HWI scientist first in world to unravel structure of key breast cancer target enzyme
8. Researchers first to see reactive oxygen species in vital enzyme
9. Disabling enzyme allows mice to gorge without becoming obese, new study finds
10. Structure of enzyme against chemical warfare agents determined
11. Researchers find pathway and enzyme unique to tularemia organism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology: